Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th September 2026 (Q2 FY26)
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI (LODR) Regulations, 2015
Audit Opinion:
Clean/Unmodified. The statutory auditors, Shah Shroff & Associates, issued an unmodified limited review report.
Auditor’s Comment:
No material misstatement noted. The review was conducted in accordance with SRE 2410, providing moderate assurance.
Key Financial Highlights [Rs. in Lakhs]
Standalone Results for Quarter Ended 30th September 2026:
Revenue from Operations: ₹7,378.87
Total Income: ₹7,527.81 (Revenue from Operations ₹7,378.87 + Other Income ₹130.61 + Other Comprehensive Income ₹18.33)
Net Profit: ₹251.80
EPS: ₹0.30 (Basic and Diluted)
Other Equity: ₹6,371.91 (as at 30th September 2026)
Cash and Cash Equivalents: ₹356.74 (as at 30th September 2026)
Debt: Total Borrowings ₹3,229.85 (Non-current ₹459.33 + Current ₹2,770.52)
Standalone Results for Half Year Ended 30th September 2026:
Revenue from Operations: ₹14,282.23 (Sum of Q1 and Q2)
Net Profit: ₹661.00
EPS: ₹0.80 (Basic and Diluted)
Comparison with Previous Periods:
Q2 FY26 Net Profit (₹251.80 lakhs) vs Q2 FY25 (₹251.80 lakhs? - Note: The data shows identical figures for some lines, but this appears to be a potential error in the source table. The half-year profit for FY26 is ₹661.00 lakhs vs FY25 ₹590.81 lakhs, indicating growth.)
Segment-wise Performance:
The company operates as a single operating segment (Pharmaceutical Formulation Manufacturing). Geographical segment revenue for Q2 FY26:
- Sales within India: ₹3,845.90 lakhs
- Sales Outside India: ₹3,532.97 lakhs
Total: ₹7,378.87 lakhs
Corporate Actions:
- Dividend: Not declared
- Appointment of M/s V. J. Talati & Co. as Cost Auditors for FY 2026-27 at a fee to be determined by the Board and members.
- Postal Ballot Notice: Approved (details not specified)
Other Significant Information:
- Significant increase in trade receivables to ₹12,020.43 lakhs (from ₹8,199.24 lakhs as of 31st March 2026).
- Increase in inventories to ₹3,417.08 lakhs (from ₹3,001.58 lakhs as of 31st March 2026).
- Increase in borrowings to ₹3,229.85 lakhs (from ₹1,883.53 lakhs as of 31st March 2026).
- Increase in trade payables to ₹8,263.78 lakhs (from ₹4,932.83 lakhs as of 31st March 2026).
Cash Flow Statement (Half Year Ended 30th September 2026):
- Net cash from operating activities: ₹432.84 lakhs
- Net cash used in investing activities: ₹(238.29) lakhs
- Net cash used in financing activities: ₹(28.50) lakhs
- Net increase in cash and cash equivalents: ₹166.05 lakhs